Cervical adenocarcinoma (CAC) refers to various cancers that are not always linked to human papillomavirus (HPV). Similarly to what has been shown with cancers of other organs, it is becoming clear that HPV status significantly impacts the prognosis of adenocarcinoma. To determine the prevalence of high-risk Human papillomavirus (hrHPV) infection in CAC and the effect this has on patient survival. From their inceptions through May1st, 2022, ClinicalTrials.gov, International ClinicalTrialsRegistryPlatform, and PubMed/Embase/Cochrane Central Register of Controlled Trials (CENTRAL) were searched. STATA 16.0 was used to analyze data on HPV infection and survival rates. In the analysis of HPV infection, 71 studies, including 11,278 people, were included, and in the analysis of prognosis, 8 research involving 1,099 participants were included. About 75% (95% CI: 0.70–0.80; 6,978 participants) of people with CAC tested positive for HPV (high-risk or low-risk), and 75% (95% CI: 0.70–0.81) of people with CAC tested positive for hrHPV (4,906 participants). The pooled infection rates for HPV-16 and -18 were 37% (95% CI 0.33-0.41, 7,848 people) and 34% (95% CI 0.30-0.38, 7,730 participants), respectively, making them the most prevalent HPVs in CAC. Improvements in overall survival (HR 0.23, 95% CI 0.11-0.47, 1013 participants), disease-free survival (HR 0.18, 95% CI 0.07-0.43, 292 participants), progression-free survival (HR 0.20, 95% CI 0.08-0.47, 271 participants), and recurrence risk (RR 0.30, 95% CI 0.07-0.43, 181 participants) were all associated with hrHPV infection. In CAC, there was an alarming prevalence of HPV infections. CAC’s most common types of HPV infection were types 16 and 18. The infection with hrHPV, on the other hand, was linked to improved survival and decreased recurrence. Further research is needed to understand better the association between hrHPV infection and other prognostic variables and to develop effective treatment plans for CAC patients with varying HPV status.
Source: sciencedirect.com/science/article/abs/pii/S0090825822005455
